MedTrace Logo

Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk

NCT05028829 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-09-23

No results posted yet for this study

Summary

Prospective randomized, multi-center, double blind placebo-controlled trial to assess the chemopreventive impact of atorvastatin (20 mg oral) vs placebo in up to 60 adults with advanced fibrosis at high risk of developing HCC.

Conditions

  • Liver Fibroses
  • Cirrhosis

Interventions

DRUG

Atorvastatin 20mg

Oral administration of atorvastatin 20 mg

DRUG

Placebo

Oral administration of placebo

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    collaborator OTHER

  • Raymond Chung

    lead OTHER

Principal Investigators

  • Raymond Chung, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-10
Primary Completion
2026-12-31
Completion
2031-03-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05028829 on ClinicalTrials.gov